It's normal for any biotech trial to be SOC + new drug vs...

First 37 Last

Share
Profile

Follow
IndexInvestor

9,048 Posts.

1472

14/08/24

16:46

Post #: 75206805
Share

Originally posted by Steini: ↑

Where is damage someone needs to be blamed. In this case, management.

So, what can we blame them for? For a bad drug performance? Actually not, as compared to existing ones on the market it performed better and saver.

For the Placebo response? How, when in the end the placebo people's statements about their personal assessment is all we got?
Was the Placebo response to be expected? To some degree yes, but not to that extent. IMO, we could hold them accountable for a too short trial duration and trial design. IMO, why did the participants on both arms still take their regular anti-depressants? Didn't that actually ask for a clouded result or is that a standard of care requirement?

Shareholders are in charge of the sp, big pharma will determine if there is value. And if yes, then that value will be independent of the actual sp as it set by the buyer / partner.

Just holding 100k shares but using this as an example to learn about what to expect when investing in stocks that develop treatments for all sorts of mental problems. Quite different to the cancer stocks, who would have thought.

GLTA

Expand

It's normal for any biotech trial to be
SOC + new drug
vs
SOC + placebo.

It would be unethical to require patients to discontinue their SOC. For one thing, some would end up on placebo only.

Yes, the trial duration could have been longer.

ACW Price at posting: 2.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

DEL

Delorean to begin selling carbon offsets under regulation changes

ASX Market Close: Index flat as miners fall | June 25, 2025

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

First 37 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 2.1¢		Change 0.000(0.00%)		Mkt cap ! $66.72M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.1¢	$34.32K	1.606M

Buyers (Bids)

No.	Vol.	Price($)
5	3166166	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	867640	4

View Market Depth

No.	Vol.	Price($)
5	3166166	0.021
10	6790100	0.020
19	4486792	0.019
11	2679332	0.018
7	4292543	0.017

Price($)	Vol.	No.
0.022	867640	4
0.023	2084880	5
0.024	1708254	5
0.025	624667	3
0.026	1579999	4

Last trade - 16.10pm 25/06/2025 (20 minute delay)

ACW (ASX) Chart

It's normal for any biotech trial to be SOC + new drug vs...

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Delorean to begin selling carbon offsets under regulation changes

ASX Market Close: Index flat as miners fall | June 25, 2025

Australia’s gas crisis is here – and dying coal plants aren’t helping

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It&apos;s normal for any biotech trial to be SOC + new drug vs...

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Delorean to begin selling carbon offsets under regulation changes

ASX Market Close: Index flat as miners fall | June 25, 2025

Australia’s gas crisis is here – and dying coal plants aren’t helping

Wednesday's HotCopper trends: DroneShield in Europe, Humm sale | June 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It's normal for any biotech trial to be SOC + new drug vs...